Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Read more about Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. Read more about Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer. Read more about Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019. Read more about The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019.
Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma. Read more about Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.
Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study. Read more about Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study.
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. Read more about The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. Read more about Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study.
Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. Read more about Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.
COVID-19 and immune checkpoint inhibitors: initial considerations. Read more about COVID-19 and immune checkpoint inhibitors: initial considerations.
